ACUR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 10:26):

Stats
Today's Volume	20 000.00
Average Volume	765.00
Market Cap	660 018
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.500
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Ross George K	Buy	50 000	Common Stock
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Skelly William G	Buy	50 000	Common Stock
2024-01-02	Skelly William G	Sell	50 000	Restricted Stock Units (2021 Plan)

INSIDER POWER
8.42
Last 100 transactions
Buy: 88 557 065 \| Sell: 8 647 538

ACURA PHARMACEUTICALS INC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ACURA PHARMACEUTICALS INC Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

ACURA PHARMACEUTICALS INC

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.